Shattuck LabsNASDAQ: STTK

AUSTIN, TX & DURHAM, NC, July 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced its addition to the Russell 2000® and Russell 3000® Indexes at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution. Shattuck's addition will be effective today when the U.S. equity markets open.

Shattuck (STTK) will now focus on higher-risk myelodysplastic syndromes and TP53 mutant acute myeloid leukemia indications for lead candidate SL-172154, following encouraging interim data from the phase IB dose expansion study.

AUSTIN, TX and DURHAM, NC, June 10, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that the U.S. FDA has granted orphan drug designation (ODD) to lead clinical candidate SL-172154 for the treatment of AML.

Noted promising complete response rates in newly diagnosed HR-MDS and TP53m AML patients as of the data cutoff on February 1, 2024; effectively transitioned responsive TP53m AML patients to hematopoietic cell transplantation.

Shattuck Labs, Inc. (STTK) reported a quarterly loss of $0.37 per share, which was better than the expected loss of $0.47 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $0.49 per share reported in the same quarter last year.

Positive results were released from the phase 1A/B study, using SL-172154 in combination with azacitidine for the treatment of patients with front-line higher-risk myelodysplastic syndrome and TP53 mutant acute myeloid leukemia. Additional results from the phase 1A/B study, using SL-172154 in combination with azacitidine for the treatment of patients with front-line HR-MDS and TP53 mutant AML, expected by mid-2024. The global myelodysplastic syndrome treatment market will reach $5.61 billion by 2032.

Shattuck Labs (NASDAQ: STTK ) stock is on the rise Wednesday after the clinical-stage biotechnology company announced results from an ongoing Phase 1a/b trial. These clinical trials cover the use of SL-172154 in combination with azacitidine in HR-MDS and TP53m Acute Myeloid Leukemia (AML) patients.

AUSTIN, TX and DURHAM, NC, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that it will host an investor call on initial data from its ongoing frontline expansion cohorts in HR-MDS and TP53m AML and review data from the poster presentation featured at the 65th ASH Annual Meeting on Wednesday, December 13, 2023 at 8:00 a.m. ET.

Shattuck Labs, Inc. (NASDAQ:STTK ) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Conor Richardson – Vice President-Investor Relations Taylor Schreiber – Scientific Co-Founder and Chief Executive Officer Lini Pandite – Chief Medical Officer Andrew Neill – Chief Financial Officer Conference Call Participants Jonathan Miller – Evercore ISI Joe Pantginis – H.C. Wainwright Marc Frahm – TD Cowen Yigal Nochomovitz – Citi Gil Blum – Needham & Company Operator Good morning and welcome to the Shattuck Labs Third Quarter 2023 Earnings Conference Call.